Ken Griffin Oramed Pharmaceuticals Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 4,000 shares of ORMP stock, worth $9,480. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,000

Holding current value

$9,480

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.21 - $2.63 $47,298 - $56,287	21,402 New	21,402 $52,000
Q4 2023 Feb 14, 2024	BUY	$1.71 - $2.57 $53,603 - $80,561	31,347 New	31,347 $72,000
Q1 2023 May 15, 2023	SELL	$1.93 - $13.1 $3,819 - $25,924	-1,979 Reduced 3.53%	54,162 $118,000
Q4 2022 Feb 14, 2023	SELL	$5.88 - $12.03 $298,263 - $610,221	-50,725 Reduced 47.47%	56,141 $675,000
Q3 2022 Nov 14, 2022	SELL	$4.6 - $9.91 $2.49 Million - $5.37 Million	-541,967 Reduced 83.53%	106,866 $692,000
Q2 2022 Aug 15, 2022	BUY	$3.72 - $9.0 $1.72 Million - $4.17 Million	463,354 Added 249.81%	648,833 $2.97 Million
Q1 2022 May 16, 2022	SELL	$8.19 - $13.89 $2.86 Million - $4.84 Million	-348,746 Reduced 65.28%	185,479 $1.61 Million
Q4 2021 Feb 14, 2022	BUY	$12.98 - $29.75 $6.69 Million - $15.3 Million	515,329 Added 2727.19%	534,225 $7.63 Million
Q3 2021 Nov 15, 2021	SELL	$12.13 - $23.82 $212,250 - $416,802	-17,498 Reduced 48.08%	18,896 $416,000
Q2 2021 Aug 16, 2021	BUY	$8.34 - $14.59 $141,438 - $247,431	16,959 Added 87.26%	36,394 $486,000
Q1 2021 May 17, 2021	SELL	$4.22 - $11.33 $55,290 - $148,445	-13,102 Reduced 40.27%	19,435 $198,000
Q3 2020 Nov 16, 2020	BUY	$2.58 - $4.16 $83,945 - $135,353	32,537 New	32,537 $85,000

Others Institutions Holding ORMP

# of Institutions

Shares Held

7.4M

Call Options Held

Put Options Held

2.1K

View Full List

About ORAMED PHARMACEUTICALS INC.

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $92M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

More about ORMP

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account